Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  SanBio Co Ltd    4592   JP3336750009

SANBIO CO LTD (4592)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

SanBio : Primary Researcher Receives 2017 Smithsonian American Ingenuity Award

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/04/2018 | 03:04pm CET

Dr. Gary Steinberg recognized for promising research with SanBio’s stem cell therapy

SanBio, Inc., a leader in regenerative cell therapies for neurological disorders, joins the Smithsonian Institution in recognizing Stanford University’s Dr. Gary Steinberg, chair of neurosurgery, for his pioneering research in the treatment of stroke patients. Steinberg received the Smithsonian’s prestigious American Ingenuity Award in Life Sciences for his unrelenting and unconventional approach to helping stroke patients regain motor function. Steinberg was the primary investigator in SanBio’s Phase 1/2a clinical trial in which stroke patients receiving SB623 demonstrated clinically significant improvement in motor function.

Said Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, “This well-deserved recognition of Dr. Steinberg’s exemplary career and ongoing research shines light on the potential of stem cell therapies like SB623 to treat patients suffering from chronic physical impairments following a stroke.”

Dr. Steinberg was honored in the Life Sciences category for his commitment to neurological research and stroke patients. He also received recognition in Smithsonian magazine.

About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo, Japan, and Mountain View, California, with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury. More information about SanBio, Inc. is available at http://sanbio.com.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANBIO CO LTD
01/04SANBIO : Primary Researcher Receives 2017 Smithsonian American Ingenuity Award
BU
2017SANBIO CO LTD : quaterly earnings release
2017SANBIO : Names Mohammad El-Kalay New Technical Operations SVP
BU
2017SANBIO CO LTD : half-yearly earnings release
2017SANBIO : $150 000 shot in the arm for STEM
AQ
2017SANBIO : South Africa finals of FemBioBiz Acceleration Competition today
AQ
2017SANBIO : BIH, NEPAD welcome applications for funding
AQ
2017SANBIO CO LTD : annual earnings release
2017SANBIO : Study of SanBio's Stem Cell Treatment for Stroke Receives Innovation Aw..
BU
2016SANBIO CO LTD : quaterly earnings release
More news
News from SeekingAlpha
2016Picking Winners Still Possible In Q1 
Financials ( JPY)
Sales 2018 605 M
EBIT 2018 -
Net income 2018 -2 643 M
Finance 2018 1 672 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 276x
EV / Sales 2019 68,6x
Capitalization 169 B
Chart SANBIO CO LTD
Duration : Period :
SanBio Co Ltd Technical Analysis Chart | 4592 | JP3336750009 | 4-Traders
Technical analysis trends SANBIO CO LTD
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 2 784  JPY
Spread / Average Target -25%
EPS Revisions
Managers
NameTitle
Keita Mori President & Representative Director
Toru Kawanishi Chairman
Damien Bates Chief Medical Officer & Head-Development
Noboru Kotani Independent Outside Director
Mohammad A. El-Kalay Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SANBIO CO LTD13.37%1 579
GILEAD SCIENCES10.83%105 375
VERTEX PHARMACEUTICALS5.16%39 931
REGENERON PHARMACEUTICALS-16.00%34 113
BIOVERATIV INC93.43%11 243
GENMAB16.62%10 343